Cancer Immunology Research

OCT 21, 2026 · JOURNAL ARTICLE

FABP4 Couples Lipid Metabolism to PD-L1 Stabilization in Immunosuppressive Myeloid Cells

Cancer Immunology Research

Abstract Metabolic dysregulation in obesity reshapes immune function, but how lipid signals drive immune suppression remains unclear. Herein, we identify a FABP4–PD-L1 axis that li

OCT 15, 2026 · JOURNAL ARTICLE

Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation

Cancer Immunology Research

Abstract T-cell exhaustion limits durable antitumor responses and remains a barrier to adoptive cell therapies (ACT) in solid tumors. To identify regulators of T-cell persistence,

OCT 12, 2026 · JOURNAL ARTICLE

TCR sensitivity shapes recognition of tumor antigen presented by host cells and TCR-T cell efficacy in solid tumors

Cancer Immunology Research

Despite advances in adoptive T cell therapy, therapeutic efficacy in solid tumors remains inconsistent, and the mechanistic determinants of treatment failure are incompletely under

OCT 5, 2026 · JOURNAL ARTICLE

A reciprocally masked anti-CD47/IL-2 fusion protein promotes antitumor immunity and limits systemic toxicity

Cancer Immunology Research

Abstract Cancer immunotherapies have achieved meaningful clinical benefit but remain limited by systemic toxicities that restrict the use of potent immune modulators. CD47-targetin

SEP 28, 2026 · JOURNAL ARTICLE

ULK1-dependent autophagy initiation promotes MHC-I degradation and immune evasion in HPV-positive head and neck cancer

Cancer Immunology Research

Abstract Antigen presentation by major histocompatibility complex class I (MHC-I) is critical for tumor cell killing by CD8+ T cells. In human papillomavirus-positive head and neck

AUG 11, 2026 · JOURNAL ARTICLE

The pre-treatment tumor microenvironment immune status determines Bacillus Calmette-Guerin immunotherapy response in early-stage bladder cancer

Cancer Immunology Research

A mechanistic study identifying a novel immunosuppressive microenvironment biomarker (MFAP2+ CAF) associated with BCG failure in bladder cancer, based on patient tumour analysis with potential for predicting response, but lacking validation in a prospective cohort or clinical trial.